4 August 2016

Touchlight shortlisted for Best Emerging UK Synthetic Biology Company.

We are delighted to announce that Touchlight has been shortlisted for the OBN 2016 Best Emerging UK Synthetic Biology Company.

The OBN Awards celebrate innovation and achievement across the UK life sciences industry and recognising achievements from emerging to late stage R&D companies as well as life sciences investors.

A judging panel comprising a range of industry experts has been assembled to decide the overall winner in each category, with the winning companies being announced at the OBN Awards Ceremony on Thursday 6th October at the Oxford Town Hall.

Read the full article here.

- ENDS -

About Touchlight

Touchlight is a privately-owned biotechnology company based in London, U.K., focussed on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as “doggybone” or dbDNA™.

dbDNA™ is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies.

Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, Touchlight DNA Services.

Issued for and on behalf of Touchlight by Instinctif Partners.

For more information please contact:

Jonny Ohlson, CEO Tim Watson / Agnes Stephens /
Tommy Duncan, CBO Katie Duffell
E: info@touchlight.com E: touchlight@instinctif.com
T: +44 20 8481 9200 T: +44 20 7457 2020